SLXN files 8-K, furnishes Exhibit 99.1 with Q3 2025 results

Rhea-AI Filing Summary

Silexion Therapeutics Corp announced it issued a press release with financial results for the third quarter ended September 30, 2025, and furnished the release as Exhibit 99.1. The company states this information is furnished and not deemed “filed” under Section 18 of the Exchange Act, and it is incorporated by reference only if specifically referenced in future filings.

Silexion’s securities listed on Nasdaq include Ordinary Shares (par value $0.0135) under ticker SLXN and Warrants (exercise price $1,552.50) under ticker SLXNW.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000202241600-0000000972NASDAQNASDAQ00020224162025-11-122025-11-120002022416slxn:OrdinarySharesParValue00135PerShareMember2025-11-122025-11-120002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2025-11-122025-11-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 12, 2025

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands		001-42253		N/A
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-756-4999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0135 per share		SLXN		The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share		SLXNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2025, Silexion Therapeutics Corp issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 2.02

The information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as may be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release, dated November 12, 2025, titled “Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: November 12, 2025	By:	/s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer

FAQ

What did Silexion (SLXN) announce in this 8-K?

Silexion furnished a press release with its financial results for the third quarter ended September 30, 2025, as Exhibit 99.1.

Which period do the results cover for Silexion (SLXN)?

The financial results cover the third quarter ended September 30, 2025.

Is the press release deemed filed under the Exchange Act?

No. The information is furnished and not deemed “filed” under Section 18 of the Exchange Act.

Where can I find Silexion’s detailed Q3 2025 results?

They are included in Exhibit 99.1 to this report.

What are Silexion’s Nasdaq tickers and security terms?

Ordinary Shares trade as SLXN (par value $0.0135). Warrants trade as SLXNW with an exercise price of $1,552.50 per share.

Where is Silexion’s principal executive office located?

12 Abba Hillel Road, Ramat-Gan, Israel 5250606.